Want more iVillage? Sign up for our
Newsletters
The diagnosis of cognitive disorders and delirium should be considered in any patient with cancer demonstrating an acute onset of agitation or uncooperative behavior, personality change, impaired cognitive functioning, altered attention span, fluctuating level of consciousness, or uncharacteristic anxiety or depression. The diagnoses of delirium and cognitive impairment are frequently missed and poorly documented, however.[1,2,3,4,5] Medical and nursing staff, as well as family members, may attribute a functional cause to some of the early, prodromal, and more subtle signs of delirium such as increased anxiety, restlessness, and emotional lability.[6] Failure to recognize delirium is particularly likely if the patient is encountered in a transient lucid phase, which can commonly occur as part of the fluctuating nature of delirium.[7] Delirium is most frequently misdiagnosed as depression or dementia.[7,8,9,10] The hypoactive subtype is considered especially likely to be misdiagnosed as depression.[7]
Differentiating delirium from dementia or recognizing delirium superimposed on dementia can be difficult because of some shared clinical features such as disorientation and impairment of memory, thinking, and judgment.[11,12,13] Dementia, however, typically appears in relatively alert individuals; disturbance of consciousness is not a common feature. The temporal onset of symptoms of delirium is acute (hours to days), not insidious (months to years) as in dementia.[14] In elderly patients with cancer, delirium is often superimposed on dementia, giving rise to a particularly difficult diagnostic challenge. In this situation, the diagnosis may become more apparent when delirium fails to reverse or when some features of delirium, especially cognitive impairment, persist. Dementia is often then the most likely explanation for a persistent or residual cognitive deficit.[14]
Vigilance on the part of nursing staff and a systematic approach to recording serial observations assist in the detection of delirium. Regular cognitive screening facilitates the diagnosis of delirium in cancer patients.[15] Instruments such as the Minimental State Examination (MMSE), Blessed Orientation Memory and Concentration Test (BOMC), and Confusion Assessment Method (CAM) have favorable psychometric properties and are brief enough to allow repeated administration in cancer patients.[16,17,18] The BOMC and MMSE screen for cognitive impairment and require active patient participation in assessment. The Bedside Confusion Scale (BCS) also requires active patient participation; however, it is remarkably brief, and its psychometric potential as a screening instrument compares favorably with the CAM.[19] The CAM does not require formal patient participation. The Memorial Delirium Assessment Scale (MDAS) and Delirium Rating Scale-Revised-98 have been validated as having diagnostic and severity rating potential.[20,21] The MDAS allows prorating of scores when a patient cannot actively participate in testing for reasons such as dyspnea or fatigue.
References:
Purpose of This Summary
This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the pathophysiology and treatment of cognitive disorders and delirium. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions.
Reviewers and Updates
This summary is reviewed regularly and updated as necessary by the PDQ Supportive and Palliative Care Editorial Board. Board members review recently published articles each month to determine whether an article should:
Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in the published articles and determine how the article should be included in the summary.
Any comments or questions about the summary content should be submitted to Cancer.gov through the Web site's Contact Form. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.
Levels of Evidence
Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Supportive and Palliative Care Editorial Board uses a formal evidence ranking system in developing its level-of-evidence designations.
Permission to Use This Summary
PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as "NCI's PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary]."
The preferred citation for this PDQ summary is:
National Cancer Institute: PDQ® Cognitive Disorders and Delirium. Bethesda, MD: National Cancer Institute. Date last modified <MM/DD/YYYY>. Available at: http://cancer.gov/cancertopics/pdq/supportivecare/delirium/HealthProfessional. Accessed <MM/DD/YYYY>.
Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in Visuals Online, a collection of over 2,000 scientific images.
Disclaimer
The information in these summaries should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the Coping with Cancer: Financial, Insurance, and Legal Information page page.
Contact Us
More information about contacting us or receiving help with the Cancer.gov Web site can be found on our Contact Us for Help page. Questions can also be submitted to Cancer.gov through the Web site's Contact Form.
Last Revised: 2011-02-04
© 1995-2011 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated. This information does not replace the advice of a doctor. Healthwise, Incorporated disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.